Busy. Please wait.
or

show password
Forgot Password?

Don't have an account?  Sign up 
or

Username is available taken
show password

why


Make sure to remember your password. If you forget it there is no way for StudyStack to send you a reset link. You would need to create a new account.
We do not share your email address with others. It is only used to allow you to reset your password. For details read our Privacy Policy and Terms of Service.


Already a StudyStack user? Log In

Reset Password
Enter the associated with your account, and we'll email you a link to reset your password.

Remove ads
Don't know
Know
remaining cards
Save
0:01
To flip the current card, click it or press the Spacebar key.  To move the current card to one of the three colored boxes, click on the box.  You may also press the UP ARROW key to move the card to the "Know" box, the DOWN ARROW key to move the card to the "Don't know" box, or the RIGHT ARROW key to move the card to the Remaining box.  You may also click on the card displayed in any of the three boxes to bring that card back to the center.

Pass complete!

"Know" box contains:
Time elapsed:
Retries:
restart all cards




share
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.

  Normal Size     Small Size show me how

BCPS study guide

biologics - MABS

QuestionAnswer
Infliximab (Remicade) --> MOA and common use used for UC and Chrohn's. chimeric monoclonal antibody that inhibits TNF. for use in moderate to severe or fistulizing disease. also used as DMARD
common toxicities for TNF alpha inhibitors infusion related, delayed hypersensitivity, inc risk of infection (rule out TB prior to use), HF exacerbations, bone marrow suppression (pancytopenia), hepatitis related to reactivation of latent HBV, vasculitis with CNS involvement
Adalimumab (Humira)--> MOA and common use humanized antibody to TNFalpha so theoretically no senstitivity reactions, moderate-severe CD and UC unresponsive to typical treatments including infliximab. also used as DMARD
certolizumab (Cimzia)--> MOA and common use Pegilated TNF humanized antibody. for moderate to severe CD unresponsive to traditional therapies. also used as DMARD
what lab value is significant with certolizumab CRP levels >10 mg/dL have better remission rates.
Golimumab (Simponi) --> MOA and common use human IgG1k antibody (anti TNF). moderate to severe UC in pts intolerant to other therapies or if need steroid continuous therapy. also used as DMARD
ADEs of golimumab similar to TNFalpha antagonists. infusion related, delayed hypersensitivity, inc risk of infection, HF exacerbations, bone marrow suppression (pancytopenia), hepatitis related to reactivation of latent HBV, vasculitis with CNS involvement
Natalizumab (Tysabri) --> MOA and common use humanized monoclonal antibody to integrin heterodimers and inhibition of alpha 4 integrin mediated leukocyte adhesion. used for moderate to severe active CD in pts with inadequate response to traditional therapies. also used for MS.
ADEs of natalizumab progressive multifocal leukoencephalopathy (REMS-TOUCH program) - watch for mental status changes and obtain LP if needed, hepatotoxicity, inc risk of infection, infusion related reactions
RANKL inhibitor - drug and use denosumab - used to prevent skeletal related events due to bone metastases from solid tumors
Biologic DMARDS infliximab, adalimumab, anakinra, rituximab, abatacept, golimumab, certolizumab pegol, toclizumab, tofacitinib
rituximab (Rituxan) --> MOA and common use CD20 antibody. used in combo with MTX to improve response in rumatoid arthritis
anakinra (Kineret) --> MOA and common use IL2 receptor antagonist. used as DMARD. do not combine with TNF antagonists or increase risk of infections.
toclizumab (Actemra) --> MOA and common use IL6 receptor antagonist. use as second line for pts who fail TNF antagonists. used as DMARD
abacept (Orencia) --> MOA and common use inhibits interaction between antigens and T cells. used in pts who don't respond to TNF antagonists. used as DMARD
tofacitinib (Xeljanz) --> MOA and common use oral Janus kinase inhibitor. typically second line DMARD and can be used as monotherapy or in combination with MTX.
etanercept (Enbrel) --> MOA and common use anti TNF. used if MTX failure. monitor for infection and check baseline PPD.
Created by: mjuhlin